Table 1.
Clinical and biological characteristics of 272 patients with HPV-positive cervical cancer, in relation to progression-free survival.
| Patients (%) | Events (%)a | PFS (p value)b | |
|---|---|---|---|
| Total | 272 (100.0) | 84 (30.9) | |
| Age | |||
| ≤50 | 140 (51.5) | 41 (29.3) | 0.40 (NS) |
| >50 | 132 (48.5) | 43 (32.6) | |
| Histologic subtype | |||
| Squamous cell carcinoma | 230 (84.6) | 71 (30.9) | 0.56 (NS) |
| Adenocarcinoma | 27 (9.9) | 8 (29.6) | |
| Adenosquamous carcinoma | 10 (3.7) | 4 (40.0) | |
| Mixed form or undifferentiated | 5 (1.8) | 1 (20.0) | |
| HPV status | |||
| Genotype 16 | 155 (57.0) | 50 (32.3) | 0.13 (NS) |
| Genotype 18 | 36 (13.2) | 14 (38.9) | |
| Genotype 45 | 27 (9.9) | 10 (37.0) | |
| Genotype 31 | 9 (3.3) | 0 (0) | |
| Genotype 33 | 11 (4.0) | 0 (0) | |
| Other genotypesc | 34 (12.5) | 10 (29.4) | |
| FIGO stage | |||
| I/II | 205 (75.4) | 50 (24.4) | <0.0001 |
| III/IV | 67 (24.6) | 34 (50.7) | |
| Nodal involvement | |||
| Yes | 167 (61.4) | 62 (37.1) | 0.0028 |
| No | 105 (38.6) | 22 (21.0) | |
| Pelvic lymph nodes | |||
| Yes | 165 (60.7) | 62 (37.6) | 0.0015 |
| No | 107 (39.3) | 22 (20.6) | |
| Para-aortic lymph nodes | |||
| Yes | 43 (15.8) | 22 (51.2) | 0.0001 |
| No | 229 (84.2) | 62 (27.1) | |
| Initial therapy | |||
| Surgery | 54 (19.9) | 10 (18.5) | 0.0008 |
| Radiotherapy | 176 (64.7) | 52 (29.5) | |
| Neoadjuvant chemotherapy | 42 (15.4) | 22 (52.4) | |
| PIK3CA mutational statusd | |||
| WT | 182 (67.7) | 60 (33.0) | 0.23 (NS) |
| Mutated | 87 (32.3) | 23 (26.4) | |
Significant results are displayed in bold.
NS not significant.
aUntil 24 months.
bLog-rank test.
cOther HPV genotypes: 39, 42, 52, 56, 58, 59, 68, 70, 73, 82.
dInformation available for 269 patients.